These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 24107267

  • 21. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF.
    Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
    [Abstract] [Full Text] [Related]

  • 22. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, Brin MF.
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [Abstract] [Full Text] [Related]

  • 23. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.
    J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
    [Abstract] [Full Text] [Related]

  • 24. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, REPOSE Principal Investigators.
    J Headache Pain; 2019 Mar 07; 20(1):26. PubMed ID: 30845917
    [Abstract] [Full Text] [Related]

  • 25. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A, Curto M, Lionetto L, Martelletti P.
    J Headache Pain; 2015 Mar 07; 17():1. PubMed ID: 26792662
    [Abstract] [Full Text] [Related]

  • 26. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 07; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 27. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU.
    Headache; 2011 Jan 07; 51(1):21-32. PubMed ID: 21070228
    [Abstract] [Full Text] [Related]

  • 28. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 29. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
    Artemenko AR, Abramov VG, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Yakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Feb 01; 123(5):89-99. PubMed ID: 37315247
    [Abstract] [Full Text] [Related]

  • 30. The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
    Silberstein SD, Diener HC, Dodick DW, Manack Adams A, DeGryse RE, Lipton RB.
    Pain Ther; 2020 Dec 01; 9(2):695-707. PubMed ID: 33026630
    [Abstract] [Full Text] [Related]

  • 31. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C.
    Cephalalgia; 2017 Dec 01; 37(14):1384-1397. PubMed ID: 28758415
    [Abstract] [Full Text] [Related]

  • 32. OnabotulinumtoxinA injection in the treatment of chronic migraine.
    Wang YF.
    Prog Brain Res; 2020 Dec 01; 255():171-206. PubMed ID: 33008506
    [Abstract] [Full Text] [Related]

  • 33. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group.
    Headache; 2019 Nov 01; 59(10):1700-1713. PubMed ID: 31559634
    [Abstract] [Full Text] [Related]

  • 34. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
    Khalil M, Zafar HW, Quarshie V, Ahmed F.
    J Headache Pain; 2014 Sep 01; 15(1):54. PubMed ID: 25178393
    [Abstract] [Full Text] [Related]

  • 35. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF.
    J Prim Care Community Health; 2020 Sep 01; 11():2150132720959936. PubMed ID: 32985341
    [Abstract] [Full Text] [Related]

  • 36. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE, Silberstein S.
    Drugs; 2018 Apr 01; 78(5):589-600. PubMed ID: 29532439
    [Abstract] [Full Text] [Related]

  • 37. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD.
    J Med Econ; 2013 Jul 01; 16(7):877-87. PubMed ID: 23647483
    [Abstract] [Full Text] [Related]

  • 38. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Jan 22; 20(1):10. PubMed ID: 30669961
    [Abstract] [Full Text] [Related]

  • 39. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM, Turkel CC, DeGryse RE, Brin MF.
    Ann N Y Acad Sci; 2014 Nov 22; 1329():67-80. PubMed ID: 25399521
    [Abstract] [Full Text] [Related]

  • 40. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group.
    Cephalalgia; 2007 Jul 22; 27(7):814-23. PubMed ID: 17441971
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.